Prostate-specific antigen in vaginal fluid as a biologic marker of condom failure
- PMID: 10382083
- DOI: 10.1016/s0010-7824(99)00013-x
Prostate-specific antigen in vaginal fluid as a biologic marker of condom failure
Abstract
Forty women participated in three clinic visits during which they were exposed to their partner's semen (10 microL, 100 microL, and 1 mL). At each visit they took vaginal fluid samples before exposure to their partner's semen, immediately after, and at 1, 24, and 48 h after exposure. PSA was measured with an enzyme-linked immunoassay. The mean PSA level for preexposure swabs ranged between 0.43 and 0.88 ng/mL. The mean PSA levels were 193 immediately after exposure to 10 microL, 472 after 100 microL, and 19,098 after 1 mL. The PSA levels declined within 1 h, and returned to background at 48 h. The findings confirm that our procedure is a sensitive and specific method for detecting recent semen exposure, and indicate that PSA levels depend on exposure intensity and time since exposure. Application of this method in condom efficacy studies provides objective evidence of condom failure that enhances the interpretation of self-report.
PIP: This article examines the efficacy of prostate-specific antigen (PSA) in vaginal fluid as a biologic marker of condom failure. The sample included 40 women who participated in three clinic visits during which they were exposed to their partner's semen (10 mcl, 100 mcl, and 1 ml). At every clinic visit, vaginal fluid samples were taken before exposure with their partner's semen, immediately after, and at 1, 24, and 48 hours after exposure; PSA was measured with an enzyme-linked immunoassay. A 0.43-0.88 ng/ml mean PSA level was found in preexposure swabs, while the mean PSA levels were 193 ng/ml immediately after exposure to 10 mcl, 472 ng/ml after exposure to 100 mcl, and 19,098 ng/ml after exposure to 1 ml. The PSA levels declined within 1 hour and returned to an original state at 48 hours. Findings show that the procedure is a sensitive and specific method for detecting recent exposure to semen and indicate that the signal intensity is a function of semen exposure and time since exposure. Application of this procedure in studies of condom efficacy provides objective evidence of condom failure, which improves the interpretation of self-reports.
Similar articles
-
Objective markers of condom failure.Sex Transm Dis. 1998 Sep;25(8):427-32. doi: 10.1097/00007435-199809000-00009. Sex Transm Dis. 1998. PMID: 9773437
-
Evaluation of prostate-specific antigen as a quantifiable indicator of condom failure in clinical trials.Contraception. 1999 Nov;60(5):289-98. doi: 10.1016/s0010-7824(99)00098-0. Contraception. 1999. PMID: 10717781 Clinical Trial.
-
Prostate-specific antigen in vaginal fluid after exposure to known amounts of semen and after condom use: comparison of self-collected and nurse-collected samples.Hum Reprod. 2008 Nov;23(11):2444-51. doi: 10.1093/humrep/den283. Epub 2008 Jul 29. Hum Reprod. 2008. PMID: 18664473
-
The use of PSA as a biomarker of recent semen exposure in female reproductive health studies.J Reprod Immunol. 2021 Nov;148:103381. doi: 10.1016/j.jri.2021.103381. Epub 2021 Sep 9. J Reprod Immunol. 2021. PMID: 34563757 Review.
-
Biomarkers of semen in the vagina: applications in clinical trials of contraception and prevention of sexually transmitted pathogens including HIV.Contraception. 2007 Jun;75(6):407-19. doi: 10.1016/j.contraception.2007.02.007. Epub 2007 Apr 30. Contraception. 2007. PMID: 17519146 Review.
Cited by
-
Differences in misreporting of sexual behavior over time: implications for HIV trials.Sex Transm Dis. 2015 Mar;42(3):160-1. doi: 10.1097/OLQ.0000000000000243. Sex Transm Dis. 2015. PMID: 25668649 Free PMC article.
-
Post-randomization Differences in Condomless Vaginal Sex Among Women Randomized to Intramuscular Depot Medroxyprogesterone Acetate Injections, a Copper Intrauterine Device or a Levonorgestrel Implant in the ECHO Trial.AIDS Behav. 2023 Mar;27(3):978-983. doi: 10.1007/s10461-022-03834-y. Epub 2022 Nov 11. AIDS Behav. 2023. PMID: 36357806 Free PMC article. Clinical Trial.
-
Improving Adherence to Post-Cervical Biopsy Sexual Abstinence in Kenyan Female Sex Workers.Am J Reprod Immunol. 2016 Jul;76(1):82-93. doi: 10.1111/aji.12520. Epub 2016 May 24. Am J Reprod Immunol. 2016. PMID: 27221472 Free PMC article. Clinical Trial.
-
A Multi-Country Cross-Sectional Study of Vaginal Carriage of Group B Streptococci (GBS) and Escherichia coli in Resource-Poor Settings: Prevalences and Risk Factors.PLoS One. 2016 Jan 26;11(1):e0148052. doi: 10.1371/journal.pone.0148052. eCollection 2016. PLoS One. 2016. PMID: 26811897 Free PMC article.
-
Effect of topical vaginal products on the detection of prostate-specific antigen, a biomarker of semen exposure, using ABAcards.Contraception. 2013 Sep;88(3):382-6. doi: 10.1016/j.contraception.2012.10.034. Epub 2012 Dec 4. Contraception. 2013. PMID: 23218862 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous